HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis

Area of Science:

• Immunology
• Neuroscience
• Molecular Biology

Background:

• CD74 is a key inflammatory factor in immune-mediated diseases, binding with macrophage migration inhibitory factor (MIF).
• Natural regulators of CD74's inflammatory role are not well understood.
• The HLA-DR molecule's regulatory role in CD74 function requires further investigation.

Purpose of the Study:

• To investigate the regulatory role of the HLA-DR molecule on CD74.
• To explore the potential of DRα1 and its derivatives as therapeutic agents for autoimmune diseases.

Main Methods:

• Utilized the HLA-DRα1 domain to study its interaction with CD74 on monocytes.
• Assessed the effect of DRα1 on MIF binding to CD74 and downstream inflammatory effects in a mouse model of experimental autoimmune encephalomyelitis (EAE).
• Investigated the impact of trypsin digestion and MOG peptide extension on DRα1's potency.

Main Results:

• The HLA-DRα1 domain directly inhibited MIF binding to CD74 and reduced inflammation in EAE mice.
• DRα1's inhibitory activity was sensitive to conformational changes, being reduced by trypsin digestion.
• A MOG peptide extension significantly enhanced DRα1's potency, creating a conformationally sensitive determinant (DRα1-MOG).
• DRα1-MOG reduced axonal damage and reversed clinical and histological signs of EAE.

Conclusions:

• DRα1 acts as a natural antagonist to MIF, with its activity potentiated by MOG peptide extension.
• The novel therapeutic DRα1-MOG-35-55 demonstrates potential for treating autoimmune diseases, including multiple sclerosis, by modulating CD74-MIF interactions.